• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

GLS-5310 DNA 新冠病毒初级疫苗增强免疫反应，随后接种 mRNA 疫苗异源加强针。

Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.

机构信息

Division of Infectious Diseases, Guro Hospital, Vaccine Innovation Center, Korea University, College of Medicine, Seoul, Republic of Korea.

GeneOne Life Science, Inc., Seoul, Republic of Korea.

出版信息

Vaccine. 2023 Jun 29;41(29):4206-4211. doi: 10.1016/j.vaccine.2023.06.013. Epub 2023 Jun 6.

DOI:10.1016/j.vaccine.2023.06.013
PMID:37296017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10242151/
Abstract

Heterologous boost regimens are being increasingly considered against SARS-CoV-2. We report results for the 32 of 45 participants in the Phase 1 CoV2-001 clinical trial (Kim et al., Int J Iinfect Dis 2023, 128:112-120) who elected to receive an EUA-approved SARS-CoV-2 mRNA vaccine 6 to 8 months following a two-dose primary vaccination with the GLS-5310 bi-cistronic DNA vaccine given intradermally and followed by application of suction using the GeneDerm device. Receipt of EUA-approved mRNA vaccines after GLS-5310 vaccination was well-tolerated, with no reported adverse events. Immune responses were enhanced such that binding antibody titers, neutralizing antibody titers, and T-cell responses increased 1,187-fold, 110-fold, and 2.9-fold, respectively. This paper is the first description of the immune responses following heterologous vaccination with a DNA primary series and mRNA boost.

摘要

针对 SARS-CoV-2，人们越来越多地考虑使用异源增强方案。我们报告了 CoV2-001 临床试验中 45 名参与者中的 32 名的结果（Kim 等人，《国际传染病杂志》2023 年，128:112-120），他们选择在接受 GLS-5310 双顺反子 DNA 疫苗（皮内给药）进行两剂初级疫苗接种 6 至 8 个月后，使用 GeneDerm 设备进行抽吸后，接种 EUA 批准的 SARS-CoV-2 mRNA 疫苗。GLS-5310 疫苗接种后接种 EUA 批准的 mRNA 疫苗耐受性良好，无不良反应报告。免疫反应增强，结合抗体滴度、中和抗体滴度和 T 细胞反应分别增加了 1187 倍、110 倍和 2.9 倍。本文首次描述了 DNA 初级系列和 mRNA 增强后的异源疫苗接种后的免疫反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/847b/10242151/c71059f06a24/gr3a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/847b/10242151/50863e7c2282/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/847b/10242151/79e4fc061139/gr2a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/847b/10242151/c71059f06a24/gr3a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/847b/10242151/50863e7c2282/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/847b/10242151/79e4fc061139/gr2a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/847b/10242151/c71059f06a24/gr3a_lrg.jpg

相似文献

1
Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.GLS-5310 DNA 新冠病毒初级疫苗增强免疫反应，随后接种 mRNA 疫苗异源加强针。
Vaccine. 2023 Jun 29;41(29):4206-4211. doi: 10.1016/j.vaccine.2023.06.013. Epub 2023 Jun 6.
2
Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device.双顺反子 GLS-5310 COVID-19 DNA 疫苗与 GeneDerm 负压吸引器联合应用的安全性和免疫原性。
Int J Infect Dis. 2023 Mar;128:112-120. doi: 10.1016/j.ijid.2022.12.037. Epub 2022 Dec 31.
3
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.两剂蛋白亚单位疫苗 MVC-COV1901 初免后加强接种多剂 mRNA 疫苗可增强针对新型 SARS-CoV-2 变异株的体液和细胞免疫应答。
Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25.
4
Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.杂合免疫改变了 SARS-CoV-2 mRNA 疫苗诱导免疫的 Fc 效应子质量。
mBio. 2022 Oct 26;13(5):e0164722. doi: 10.1128/mbio.01647-22. Epub 2022 Aug 24.
5
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.新型冠状病毒 ARCoV mRNA 疫苗在中国成年人中的安全性和免疫原性：一项随机、双盲、安慰剂对照、1 期临床试验。
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.
6
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.异源加强免疫用腺病毒 5 型载体和基于蛋白亚单位的 COVID-19 疫苗（Convidecia/ZF2001）的安全性和免疫原性：一项随机、观察者设盲、安慰剂对照试验。
PLoS Med. 2022 May 26;19(5):e1003953. doi: 10.1371/journal.pmed.1003953. eCollection 2022 May.
7
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].不同 COVID-19 疫苗组合在健康个体中的安全性和免疫原性评估：一项随机、设盲、对照的 3 期临床试验 [PRIBIVAC] 的研究方案。
Trials. 2022 Jun 16;23(1):498. doi: 10.1186/s13063-022-06345-2.
8
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
9
Durability of Heterologous and Homologous COVID-19 Vaccine Boosts.异源和同源 COVID-19 疫苗加强针的持久性。
JAMA Netw Open. 2022 Aug 1;5(8):e2226335. doi: 10.1001/jamanetworkopen.2022.26335.
10
Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.研究癌症患者接种第三和第四剂 COVID-19 疫苗的免疫反应效果和持久性：一项单臂临床试验。
Elife. 2023 Mar 28;12:e83694. doi: 10.7554/eLife.83694.

本文引用的文献

1
A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.异源 AZD1222 疫苗初免和 BNT162b2 疫苗加强免疫方案比同源 BNT162b2 疫苗方案更有效地诱导中和抗体，但不能诱导记忆 T 细胞。
Vaccine. 2023 Mar 3;41(10):1694-1702. doi: 10.1016/j.vaccine.2023.01.063. Epub 2023 Feb 6.
2
Susceptibility to reinfection with SARS-CoV-2 virus relative to existing antibody concentrations and T cell response.相对于现有抗体浓度和 T 细胞反应，对 SARS-CoV-2 病毒再次感染的易感性。
Int J Infect Dis. 2023 Jun;131:100-110. doi: 10.1016/j.ijid.2023.01.006. Epub 2023 Jan 24.
3
Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device.
双顺反子 GLS-5310 COVID-19 DNA 疫苗与 GeneDerm 负压吸引器联合应用的安全性和免疫原性。
Int J Infect Dis. 2023 Mar;128:112-120. doi: 10.1016/j.ijid.2022.12.037. Epub 2022 Dec 31.
4
Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron.韩国队列中的异源ChAdOx1-BNT162b2疫苗接种可诱导包括奥密克戎在内的强烈免疫和抗体反应。
iScience. 2022 Jun 17;25(6):104473. doi: 10.1016/j.isci.2022.104473. Epub 2022 May 26.
5
Humoral and Cellular Responses to COVID-19 Vaccines in SARS-CoV-2 Infection-Naïve and -Recovered Korean Individuals.新冠病毒感染初免和康复的韩国个体对新冠疫苗的体液和细胞免疫反应
Vaccines (Basel). 2022 Feb 18;10(2):332. doi: 10.3390/vaccines10020332.
6
Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination.异源 ChAdOx1/mRNA-1273 疫苗接种诱导广泛的抗 SARS-CoV-2 抗体免疫。
Science. 2022 Mar 4;375(6584):1041-1047. doi: 10.1126/science.abn2688. Epub 2022 Feb 10.
7
SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.SARS-CoV-2 疫苗接种可诱导能够交叉识别 Alpha 到奥密克戎变体的免疫 T 细胞记忆。
Cell. 2022 Mar 3;185(5):847-859.e11. doi: 10.1016/j.cell.2022.01.015. Epub 2022 Jan 24.
8
Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.细胞和体液免疫应答在异源和同源 SARS-CoV-2 疫苗接种中的相互关系。
Allergy. 2022 Aug;77(8):2381-2392. doi: 10.1111/all.15247. Epub 2022 Feb 16.
9
Homologous and Heterologous Covid-19 Booster Vaccinations.同源和异源 COVID-19 加强针接种。
N Engl J Med. 2022 Mar 17;386(11):1046-1057. doi: 10.1056/NEJMoa2116414. Epub 2022 Jan 26.
10
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.在英国，用 ChAdOx1 nCov-19 或 BNT162b2 接种两剂后作为第三剂（加强针）接种 7 种 COVID-19 疫苗的安全性和免疫原性（COV-BOOST）：一项盲法、多中心、随机、对照、2 期试验。
Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2.